Patents Assigned to DEPARTMENT OF MEDICAL SCIENCES
-
Patent number: 9557341Abstract: The present invention provides a method of predicting the risk of a patient for developing cutaneous adverse drug reaction to non-nucleoside reverse transcriptase inhibitors such as nevirapine by using HLA-B*3505 allele and/or polymorphisms in the CCHCR1 gene.Type: GrantFiled: December 11, 2009Date of Patent: January 31, 2017Assignees: MAHIDOL UNIVERSITY, RIKEN, DEPARTMENT OF MEDICAL SCIENCES, MINISTRY OF PUBLIC, THAILAND CENTER OF EXCELLENCE FOR LIFE SCIENCES (OKMD)Inventors: Somnuek Sungkanuparph, Sasisopin Kiertiburanakul, Thanyachai Sura, Wasun Chantratita, Soranun Chantarangsu, Angkana Charoenyingwattana, Surakameth Mahasirimongkol, Michiaki Kubo, Taisei Mushiroda, Yusuke Nakamura
-
Publication number: 20160264648Abstract: From PBMCs of patients infected with H1N1pdm, three human monoclonal antibodies have been obtained which are capable of binding to an epitope present at residues 40 to 58 in an HA2 region of a hemagglutinin protein derived from H1N1pdm. Further, these antibodies have been found to also have a neutralization activity against subtype H1 and subtype H5 of group 1 influenza A viruses. On the other hand, the three antibodies have also been found to exhibit neither a binding ability nor a neutralization activity against subtype H2 which belongs to the group 1, but in the HA2 region derived from H1N1pdm of which the amino acid at residue 45 is substituted with phenylalanine and the amino acid at residue 47 is substituted with glycine.Type: ApplicationFiled: November 6, 2014Publication date: September 15, 2016Applicants: OSAKA UNIVERSITY, MEDICAL & BIOLOGICAL LABORATORIES CO., LTD., DEPARTMENT OF MEDICAL SCIENCESInventors: Tadahiro SASAKI, Kenichiro ONO, Naphatsawan BOONSATHORN, Yohei WATANABE, Yuji INOUE, Kazuyoshi IKUTA
-
Patent number: 9181328Abstract: Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.Type: GrantFiled: January 31, 2013Date of Patent: November 10, 2015Assignees: OSAKA UNIVERSITY, THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY, MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD., DEPARTMENT OF MEDICAL SCIENCES MINISTRY OF PUBLIC HEALTHInventors: Mayo Yasugi, Motoki Kuhara, Jotika Boon-Long, Kazuhito Fujiyama, Ritsuko Koketsu, Kazuyoshi Ikuta
-
Publication number: 20140377262Abstract: Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.Type: ApplicationFiled: January 31, 2013Publication date: December 25, 2014Applicants: OSAKA UNIVERSITY, THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY, MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD., DEPARTMENT OF MEDICAL SCIENCESInventors: Mayo Yasugi, Motoki Kuhara, Jotika Boon-Long, Kazuhito Fujiyama, Ritsuko Koketsu, Kazuyoshi Ikuta
-
Publication number: 20110301043Abstract: The present invention provides a method of predicting the risk of a patient for developing cutaneous adverse drug reaction to non-nucleoside reverse transcriptase inhibitors such as nevirapine by using HLA-B*3505 allele and/or polymorphisms in the CCHCR1 gene.Type: ApplicationFiled: December 11, 2009Publication date: December 8, 2011Applicants: MAHIDOL UNIVERSITY, RIKEN, DEPARTMENT OF MEDICAL SCIENCESInventors: Somnuek Sungkanuparph, Sasisopin Kiertiburanakul, Thanyachai Sura, Wasun Chantratita, Soranun Chantarangsu, Angkana Charoenyingwattana, Surakameth Mahasirimongkol, Michiaki Kubo, Taisei Mushiroda, Yusuke Nakamura
-
Patent number: 7670610Abstract: A recombinant BCG vaccine being transformed with an expression vector that has a polynucleotide encoding a foreign antigenic protein, wherein the polynucleotide is a modified one in which the third position of each codon is substituted with G or C without a change of an amino acid. This recombinant BCG vaccine has an excellent expression rate of antigenic protein and, as a result, capable of inducing a sufficient immune response against target infectious disease, cancer, or the like at the same dose as that of the typical BCG vaccine.Type: GrantFiled: September 5, 2008Date of Patent: March 2, 2010Assignee: Department of Medical Sciences-Ministry of Public Health of ThailandInventors: Mitsuo Honda, Kazuhiro Matsuo, Masaru Kanekiyo, Duanthanorm Promkhatkaew
-
Patent number: 7638133Abstract: A recombinant BCG vaccine being transformed with an expression vector that has a polynucleotide encoding a foreign antigenic protein, wherein the polynucleotide is a modified one in which the third position of each codon is substituted with G or C without a change of an amino acid. This recombinant BCG vaccine has an excellent expression rate of antigenic protein and, as a result, capable of inducing a sufficient immune response against target infectious disease, cancer, or the like at the same dose as that of the typical BCG vaccine.Type: GrantFiled: August 13, 2003Date of Patent: December 29, 2009Assignee: Department of Medical Sciences Ministry of Public Health of ThailandInventors: Mitsuo Honda, Kazuhiro Matsuo, Masaru Kanekiyo, Duanthanorm Promkhatkaew